Frontiers in Immunology · 2022 · 24 citations · 34 references
Life SciencesPharmacologyPharmacotherapyGastrointestinal PharmacotherapyInflammationMucosal ImmunologyGastrointestinal InflammationGastrointestinal PharmacologyGut MicrobiotaInflammatory Bowel DiseaseIntestinal Barrier FunctionMucosal Barrier FunctionGastrointestinal Barrier DysfunctionGut Barrier DisruptionGut Barrier FunctionGut Epithelial Barrier FunctionGut Microbiome DysbiosisGut Microbiota DysbiosisIntestinal Epithelial Barrier FunctionProton Pump Inhibition
Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically susceptible individuals. Proton pump inhibitors (PPIs) such as rabeprazole are frequently employed for gastric acid inhibition. However, long-term PPI administration can alter the intestinal microbiome composition, possibly worsening IBD severity. The present study revealed that tegoprazan, a potassium-competitive acid blocker, significantly improved colitis in mice and enhanced the intestinal epithelial barrier function. Tegoprazan alleviated gut microbiota dysbiosis and enhanced the growth of Bacteroides vulgatus . In turn, B. vulgatus alleviated intestinal inflammation by inhibiting epithelial adhesion of pathogenic bacteria. Unlike rabeprazole, tegoprazan did not induce gut dysbiosis. Our findings provide novel insights into the potential role of tegoprazan as an intestinal protectant for IBD and as a therapeutic agent for gastric acid-related diseases.
34
Structure, function and diversity of the healthy human microbiome
Curtis Huttenhower, J. Fah Sathirapongsasuti, Nicola Segata et al. · Nature · 2012 · 11.9K citations · Full text
Life Sciences, Biology, Microbiology +17
Daniel N. Frank, Allison L. St. Amand, Robert A. Feldman et al. · Proceedings of the National Academy of Sciences · 2007 · 4.6K citations · Full text
Proton pump inhibitors affect the gut microbiome
Floris Imhann, Marc Jan Bonder, Arnau Vich Vila et al. · Gut · 2015 · 1.3K citations · Full text
Long-term Proton Pump Inhibitor Therapy and Risk of Hip Fracture
Yu‐Xiao Yang, James D. Lewis, Solomon Epstein et al. · JAMA · 2006 · 1.2K citations